If You Invested in GRI Bio, Inc. (GRI)

GRI Bio, Inc. (NASDAQ: GRI) is a clinical-stage biopharmaceutical company developing therapies for inflammatory, fibrotic and autoimmune diseases. The company focuses on modulating the activity of Natural Killer T (NKT) cells, which it describes as key regulators early in the inflammatory cascade and a functional link between the innate and adaptive immune responses. By targeting these immune cells, GRI Bio aims to interrupt disease progression and help restore the immune system to homeostasis.

According to the company’s disclosures, Type I invariant NKT (iNKT) cells play a critical role in propagating injury, inflammation and fibrosis in inflammatory and fibrotic indications. GRI Bio’s programs are built around inhibiting or activating specific NKT cell subsets to influence these disease processes. The company reports having a library of over 500 proprietary compounds, which it views as a source for a growing pipeline of immune cell modulators.

Core pipeline and therapeutic focus

GRI Bio’s lead program, GRI-0621, is described as an oral therapeutic being developed for idiopathic pulmonary fibrosis (IPF), a serious fibrotic lung disease with significant unmet medical need. In the company’s news releases and SEC filings, GRI-0621 is characterized as:

• An RARβγ agonist that inhibits the activity of key immune cells, including iNKT cells.
• A small molecule related to oral tazarotene, with receptor selectivity that has been evaluated in earlier studies in over 1,700 patients treated for up to 52 weeks.
• A candidate intended to act as both an immunomodulator and an anti-fibrotic agent, based on the company’s interpretation of clinical and biomarker data.

The company has conducted a Phase 2a randomized, double-blind, placebo-controlled study of GRI-0621 in IPF (GRI-0621-IPF-02). As described in its press releases and an 8-K filing, this trial enrolled 35 subjects with IPF, randomized 2:1 to receive GRI-0621 or placebo once daily for 12 weeks, with a sub-study evaluating immune cells in bronchoalveolar lavage fluid. The primary endpoint was safety and tolerability, with secondary endpoints including serum biomarkers, pharmacokinetics and pharmacodynamic measures of immune cell activation, and exploratory endpoints assessing pulmonary function and additional mechanistic readouts.

GRI Bio has also disclosed a pipeline of novel type 2 diverse NKT (dNKT) agonists in development for systemic lupus erythematosus. These candidates are intended to modulate type 2 NKT cells, which the company positions as part of its broader strategy to use NKT cell biology to address autoimmune disorders.

Mechanistic approach and disease biology

In its public communications, GRI Bio emphasizes the role of NKT cells in disease mechanisms. NKT cells are described as innate-like T cells sharing properties of both NK and T cells, acting as an early checkpoint in immune activation. The company highlights that:

• iNKT cells are implicated in the injury, inflammatory response and fibrosis observed in inflammatory and fibrotic conditions.
• Type 2 dNKT cells represent a distinct subset that can be targeted with agonists for autoimmune indications.

For IPF, GRI Bio reports that GRI-0621 has shown effects on collagen turnover biomarkers, alveolar basement membrane repair markers, and forced vital capacity (FVC) in its Phase 2a study. Company materials describe:

• Changes in biomarkers of type I, III, IV and VI collagen consistent with an anti-fibrotic profile and potential initiation of lung tissue repair mechanisms.
• Placebo-adjusted increases in FVC at 6 and 12 weeks in GRI-0621-treated subjects, with a higher proportion of treated subjects experiencing FVC increases compared to placebo in the reported dataset.
• Immune profiling data indicating inhibition of iNKT activity and a shift toward an anti-fibrotic cytokine profile, including higher interferon-gamma and lower levels of several pro-fibrotic cytokines.

These findings are presented by the company as supporting a disease-modifying mechanism in IPF, though they remain subject to further clinical development and regulatory review.

Clinical-stage biopharmaceutical profile

GRI Bio describes itself consistently in its press releases and SEC filings as a clinical-stage biopharmaceutical company. Its activities center on:

• Conducting clinical trials of GRI-0621 in IPF, including safety, biomarker and lung function assessments.
• Advancing preclinical and early-stage programs in type 2 dNKT agonists for systemic lupus erythematosus.
• Maintaining and expanding a proprietary compound library to support future pipeline candidates.

The company is incorporated in Delaware and is classified under the Pharmaceutical Preparation Manufacturing industry within the Manufacturing sector, as indicated in its registration statement. Its principal executive offices are located in La Jolla, California, as reflected in multiple SEC filings.

Capital markets and listing

GRI Bio’s common stock trades on Nasdaq under the ticker symbol GRI. The company has used public equity offerings and warrants to fund its operations. In December 2025, it reported via press release and Form 8-K that it closed a best efforts public offering of common stock, pre-funded warrants and Series F warrants, and stated that, immediately following completion of the offering, its stockholders’ equity exceeded the minimum Nasdaq requirement of $2.5 million.

The company has also filed a registration statement on Form S-1 and subsequent amendments to register securities for these offerings, and has disclosed various warrant and purchase agreement structures in its exhibits. These filings illustrate GRI Bio’s use of the U.S. public capital markets to support product candidate development, working capital and general corporate purposes.

Regulatory and governance context

As a U.S. public company, GRI Bio files periodic and current reports with the U.S. Securities and Exchange Commission, including Forms 10-K, 10-Q, 8-K and proxy statements. Its Definitive Proxy Statement (DEF 14A) describes a board of directors structure, equity incentive plans and other governance arrangements typical of smaller reporting and emerging growth companies. The company identifies itself as a smaller reporting company and an emerging growth company in its S-1/A filing.

For investors and analysts, GRI Bio represents a clinical-stage, micro- to small-cap biotechnology issuer whose value is closely tied to the progress, safety profile and efficacy signals of its NKT cell–modulating pipeline, particularly GRI-0621 in IPF and its early-stage dNKT agonist programs in systemic lupus erythematosus.

Key points for GRI stock research

• Business focus: Clinical-stage biopharmaceutical development targeting NKT cells in inflammatory, fibrotic and autoimmune diseases.
• Lead asset: GRI-0621, an oral RARβγ agonist and iNKT activity inhibitor in Phase 2a development for idiopathic pulmonary fibrosis.
• Pipeline: Type 2 dNKT agonists in development for systemic lupus erythematosus, supported by a proprietary compound library.
• Listing: Common stock listed on Nasdaq under the symbol GRI.
• Location and structure: Delaware corporation with principal executive offices in La Jolla, California; categorized in Pharmaceutical Preparation Manufacturing.
• Stage of development: Clinical-stage, with reported Phase 2a safety, biomarker and lung function data in IPF.